Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027

Business Wire February 12, 2020

Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027

Business Wire February 10, 2020

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines

Business Wire February 6, 2020

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

Business Wire January 10, 2020

Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 9, 2020

Revance Provides Corporate Update and Anticipated Milestones for 2020

Business Wire January 9, 2020

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

Business Wire December 5, 2019

Revance Announces Pricing of Public Offering of Common Stock

Business Wire December 4, 2019

Revance Announces Proposed Public Offering of Common Stock

Business Wire December 3, 2019

Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

Business Wire December 2, 2019

Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

Business Wire November 25, 2019

Revance to Participate in the Stifel 2019 Healthcare Conference

Business Wire November 12, 2019

Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference

Business Wire November 6, 2019

Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update

Business Wire November 4, 2019

Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

Business Wire November 4, 2019

Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

Business Wire November 4, 2019

Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019

Business Wire October 28, 2019

Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting

Business Wire October 23, 2019

Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

Business Wire October 14, 2019

Revance Earns Great Place to Work® Certification for Second Year

Business Wire October 2, 2019